VTRS vs. UTHR, SRPT, RDY, BMRN, BGNE, CTLT, ELAN, LEGN, CERE, and TEVA
Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), BioMarin Pharmaceutical (BMRN), BeiGene (BGNE), Catalent (CTLT), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical preparations" industry.
United Therapeutics (NASDAQ:UTHR) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership, profitability and earnings.
In the previous week, United Therapeutics had 8 more articles in the media than Viatris. MarketBeat recorded 12 mentions for United Therapeutics and 4 mentions for Viatris. Viatris' average media sentiment score of 1.07 beat United Therapeutics' score of 0.62 indicating that United Therapeutics is being referred to more favorably in the media.
United Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
United Therapeutics has a net margin of 42.05% compared to United Therapeutics' net margin of -0.37%. Viatris' return on equity of 18.72% beat United Therapeutics' return on equity.
United Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Viatris has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
United Therapeutics currently has a consensus target price of $309.44, suggesting a potential upside of 14.93%. Viatris has a consensus target price of $11.00, suggesting a potential upside of 4.56%. Given Viatris' stronger consensus rating and higher possible upside, research analysts plainly believe United Therapeutics is more favorable than Viatris.
94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 12.5% of United Therapeutics shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
United Therapeutics received 550 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 61.80% of users gave United Therapeutics an outperform vote while only 35.59% of users gave Viatris an outperform vote.
Summary
United Therapeutics beats Viatris on 16 of the 18 factors compared between the two stocks.
Get Viatris News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
